Compare Cassava Sciences Inc (FLNA) vs Honest Company Inc (HNST) Price & Performance

FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.

The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.

HNST trades at $4.97, up 0.81% with a bearish technical signal despite recent earnings beat. The company shows mixed fundamentals with declining revenue but improving cash flow trends. Recent Q2 2026 results exceeded expectations with $0.04 EPS versus $0.00926 estimate, while institutional interest grows with BlackRock's $25.66 million investment.

The stock faces headwinds from negative profitability metrics and declining sales, but strategic exits are driving margin improvement. Analyst consensus suggests modest upside to $5.30 target, though execution risks remain high given the ongoing turnaround efforts and competitive pressures in personal care markets.